1. |
Growth hormone debate reaches new heights |
|
Inpharma Weekly,
Volume &NA;,
Issue 1226,
2000,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
2. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1226,
2000,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
3. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1226,
2000,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
4. |
Impact of COX-2 inhibitors at US health plan disappointing |
|
Inpharma Weekly,
Volume &NA;,
Issue 1226,
2000,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
5. |
New treatments for rotavirus infection? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1226,
2000,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
6. |
Ketolides tackle Gram-positive resistance |
|
Inpharma Weekly,
Volume &NA;,
Issue 1226,
2000,
Page 7-8
Pamela Hunter,
Preview
|
|
摘要:
Recent years have seen a steady rise in the incidence of resistance to standard antibacterial agents in many bacterial species, but especially among Gram-positive cocci. This resistance is often to many agents of differing classes and in some cases the options for treatment of infections caused by these organisms are extremely limited. Resistance to β-lactam agents, including penicillins and cephalosporins, appeared some years ago and has now become widespread in staphylococci and in pneumococci. This resistance is frequently accompanied by resistance to the macrolides, an important group of agents often used as an alternative to penicillins. Various modifications have been made to the basic structure of the macrolides, resulting in the most recent compounds, the ketolides. These compounds have greater antibacterial activity than the macrolides, and retain activity against many macrolide-resistant Gram-positive organisms. At the 5th International Congress on Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones [Seville, Spain; January 2000], considerable time was devoted to describing the properties of 2 lead ketolides, telithromycin [HMR 3647] and ABT 773.
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
7. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1226,
2000,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
8. |
rhPM-1 beneficial in Castleman's disease |
|
Inpharma Weekly,
Volume &NA;,
Issue 1226,
2000,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
9. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1226,
2000,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
10. |
NHL gets the CHOP with rituximab |
|
Inpharma Weekly,
Volume &NA;,
Issue 1226,
2000,
Page 11-12
Carmen Innes,
Preview
|
|
摘要:
Rituximab, already indicated for the treatment of patients with low-grade or follicular non-Hodgkin's lymphoma (NHL), is now also looking promising in the intermediate- or high-grade setting. In a small phase II study, 97% of patients with previously untreated intermediate- or high-grade NHL had a response to rituximab plus CHOP*therapy. Meanwhile, 3-year data from another phase II trial showed that 100% of patients with low-grade or follicular NHL achieved a response to rituximab plus CHOP. The trials were reported at the 41st Annual Meeting of the American Society of Hematology [New Orleans, US; December 1999].
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|